T. Rowe Price Associates’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-22,659
| Closed | -$2.11M | – | 3057 |
|
|
2021
Q4 | $2.11M | Sell |
22,659
-7,572
| -25% | -$499K | ﹤0.01% | 1692 |
|
|
2021
Q3 | $1.8M | Buy |
30,231
+268
| +0.9% | +$15.8K | ﹤0.01% | 1770 |
|
|
2021
Q2 | $2.04M | Sell |
29,963
-2,227
| -7% | -$145K | ﹤0.01% | 1728 |
|
|
2021
Q1 | $2.23M | Buy |
32,190
+2,596
| +9% | +$200K | ﹤0.01% | 1673 |
|
|
2020
Q4 | $2.27M | Buy |
29,594
+1,460
| +5% | +$109K | ﹤0.01% | 1591 |
|
|
2020
Q3 | $2.1M | Buy |
28,134
+2,503
| +10% | +$167K | ﹤0.01% | 1545 |
|
|
2020
Q2 | $1.61M | Buy |
25,631
+1,072
| +4% | +$59K | ﹤0.01% | 1598 |
|
|
2020
Q1 | $1.03M | Buy |
24,559
+303
| +1% | +$13.9K | ﹤0.01% | 1685 |
|
|
2019
Q4 | $1.1M | Buy |
24,256
+2,014
| +9% | +$95.2K | ﹤0.01% | 1850 |
|
|
2019
Q3 | $1.02M | Buy |
22,242
+234
| +1% | +$13.2K | ﹤0.01% | 1817 |
|
|
2019
Q2 | $1.29M | Buy |
22,008
+127
| +0.6% | +$6.56K | ﹤0.01% | 1740 |
|
|
2019
Q1 | $981K | Buy |
21,881
+140
| +0.6% | +$6.42K | ﹤0.01% | 1846 |
|
|
2018
Q4 | $847K | Buy |
21,741
+86
| +0.4% | +$3.38K | ﹤0.01% | 1870 |
|
|
2018
Q3 | $997K | Buy |
21,655
+4,793
| +28% | +$194K | ﹤0.01% | 1881 |
|
|
2018
Q2 | $735K | Buy |
16,862
+1,955
| +13% | +$84K | ﹤0.01% | 1977 |
|
|
2018
Q1 | $589K | Buy |
14,907
+130
| +0.9% | +$5.06K | ﹤0.01% | 2022 |
|
|
2017
Q4 | $502K | Buy |
14,777
+20
| +0.1% | +$570 | ﹤0.01% | 2087 |
|
|
2017
Q3 | $376K | Hold |
14,757
| – | – | ﹤0.01% | 2194 |
|
|
2017
Q2 | $249K | Buy |
14,757
+27
| +0.2% | +$370 | ﹤0.01% | 2302 |
|
|
2017
Q1 | $215K | Hold |
14,730
| – | – | ﹤0.01% | 2375 |
|
|
2016
Q4 | $209K | Buy |
14,730
+9,500
| +182% | +$147K | ﹤0.01% | 2374 |
|
|
2016
Q3 | $92K | Hold |
5,230
| – | – | ﹤0.01% | 2455 |
|
|
2016
Q2 | $89K | Hold |
5,230
| – | – | ﹤0.01% | 2440 |
|
|
2016
Q1 | $103K | Hold |
5,230
| – | – | ﹤0.01% | 2411 |
|
|
2015
Q4 | $99K | Sell |
5,230
-6,870
| -57% | -$140K | ﹤0.01% | 2426 |
|
|
2015
Q3 | $231K | Hold |
12,100
| – | – | ﹤0.01% | 2246 |
|
|
2015
Q2 | $561K | Buy |
12,100
+2,560
| +27% | +$111K | ﹤0.01% | 1951 |
|
|
2015
Q1 | $417K | Buy |
9,540
+1,630
| +21% | +$75.8K | ﹤0.01% | 2055 |
|
|
2014
Q4 | $274K | Buy |
7,910
+1,650
| +26% | +$67K | ﹤0.01% | 2216 |
|
|
2014
Q3 | $262K | Hold |
6,260
| – | – | ﹤0.01% | 2210 |
|
|
2014
Q2 | $367K | Buy |
6,260
+700
| +13% | +$44.1K | ﹤0.01% | 2081 |
|
|
2014
Q1 | $350K | Hold |
5,560
| – | – | ﹤0.01% | 2087 |
|
|
2013
Q4 | $325K | Sell |
5,560
-2,640
| -32% | -$138K | ﹤0.01% | 2105 |
|
|
2013
Q3 | $432K | Sell |
8,200
-1,570
| -16% | -$105K | ﹤0.01% | 1945 |
|
|
2013
Q2 | $752K | Buy |
+9,770
| New | +$798K | ﹤0.01% | 1728 |
|
T. Rowe Price Associates's ARNA Position: Q1 2022 in Review
T. Rowe Price Associates sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 22,659 shares — an estimated $2.11M sold.
T. Rowe Price Associates first reported a position in ARNA in Q2 2013 and held it in 35 quarters. The position peaked at $2.27M in Q4 2020. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- T. Rowe Price Associates reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- T. Rowe Price Associates sold 22,659 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $2.11M.
- T. Rowe Price Associates first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 35 quarters.
- T. Rowe Price Associates's Arena Pharmaceuticals Inc position peaked at $2.27M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.